BR112015022465A2 - método para tratamento não-tóxico para síndrome de abstinência de drogas - Google Patents

método para tratamento não-tóxico para síndrome de abstinência de drogas

Info

Publication number
BR112015022465A2
BR112015022465A2 BR112015022465A BR112015022465A BR112015022465A2 BR 112015022465 A2 BR112015022465 A2 BR 112015022465A2 BR 112015022465 A BR112015022465 A BR 112015022465A BR 112015022465 A BR112015022465 A BR 112015022465A BR 112015022465 A2 BR112015022465 A2 BR 112015022465A2
Authority
BR
Brazil
Prior art keywords
withdrawal syndrome
drug withdrawal
treatment method
toxic treatment
drug
Prior art date
Application number
BR112015022465A
Other languages
English (en)
Inventor
Friedhoff Lawrence
Original Assignee
Demerx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Demerx Inc filed Critical Demerx Inc
Publication of BR112015022465A2 publication Critical patent/BR112015022465A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Abstract

resumo patente de invenção: "método para tratamento não-tóxico para síndrome de abstinência de drogas". a divulgação fornece um método para administrar noribogaína a um paciente humano com vício em droga em dosagens que proporcionem eficácia sem levar a nenhum sinal clínico prejudicial significativo. 1/1
BR112015022465A 2013-03-15 2014-03-14 método para tratamento não-tóxico para síndrome de abstinência de drogas BR112015022465A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361852485P 2013-03-15 2013-03-15
PCT/US2014/028946 WO2014144508A2 (en) 2013-03-15 2014-03-14 Method for non-toxic treatment for drug withdrawal

Publications (1)

Publication Number Publication Date
BR112015022465A2 true BR112015022465A2 (pt) 2017-07-18

Family

ID=51537436

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022465A BR112015022465A2 (pt) 2013-03-15 2014-03-14 método para tratamento não-tóxico para síndrome de abstinência de drogas

Country Status (14)

Country Link
US (3) US20160271139A1 (pt)
EP (1) EP2968355A4 (pt)
JP (1) JP2016514679A (pt)
KR (1) KR20150130461A (pt)
CN (1) CN105307658A (pt)
AR (1) AR095338A1 (pt)
AU (1) AU2014228986A1 (pt)
BR (1) BR112015022465A2 (pt)
CA (2) CA2942638A1 (pt)
EA (1) EA201591679A1 (pt)
HK (1) HK1220381A1 (pt)
TW (1) TW201505634A (pt)
WO (2) WO2014143201A1 (pt)
ZA (1) ZA201507514B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036540A2 (en) 2006-09-20 2008-03-27 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
CA2942638A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
WO2015126836A2 (en) * 2014-02-18 2015-08-27 Demerx, Inc. Therapeutic methods employing noribogaine and related compounds
AU2014383143A1 (en) 2014-02-18 2016-09-29 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
AU2015353414B2 (en) 2014-11-26 2021-04-29 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
WO2016134019A1 (en) * 2015-02-19 2016-08-25 Demerx, Inc. Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors
CA3024081A1 (en) * 2015-05-11 2016-11-17 Demerx, Inc. Methods for treatment of opioid dependency and withdrawal using noribogaine
JP6832946B2 (ja) 2015-11-17 2021-02-24 アエリエ ファーマシューティカルズ インコーポレイテッド キナーゼ阻害剤およびその中間体の調製方法
KR102409785B1 (ko) 2017-03-23 2022-06-16 삼성전자주식회사 무선 통신 시스템에서 초기 접속을 수행하기 위한 장치 및 방법
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138094A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
GB2620323A (en) * 2019-07-15 2024-01-03 Demerx Inc Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2817623A (en) 1956-03-22 1957-12-24 Ciba Pharm Prod Inc Tabernanthine, ibogaine containing analgesic compositions
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
AU4613296A (en) * 1994-07-25 1996-04-19 Nda International, Inc. A method of treating chemical dependency in mammals and a composition therefor
US5591738A (en) 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US5616575A (en) 1995-12-04 1997-04-01 Regents Of The University Of Minnesota Bioactive tricyclic ibogaine analogs
ES2224430T3 (es) * 1997-09-04 2005-03-01 Novoneuron Inc Noribogaina en el tratamiento del dolor y de la toxicomania.
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
US6416793B1 (en) 2000-07-11 2002-07-09 Bioresponse, L.L.C. Formulations and use of controlled-release indole alkaloids
US20030153552A1 (en) 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
US6939538B2 (en) * 2002-04-11 2005-09-06 Biomedical Research Models, Inc. Extended release analgesic for pain control
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
US20060229293A1 (en) 2005-04-06 2006-10-12 Addiction Research Institute, Inc. Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9358237B2 (en) 2010-07-23 2016-06-07 Demerx, Inc. Noribogaine compositions
WO2012024401A2 (en) 2010-08-17 2012-02-23 University Of Florida Research Foundation, Inc. Intelligent drug and/or fluid delivery system to optimizing medical treatment or therapy using pharmacodynamic and/or pharmacokinetic data
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
EP2685979B1 (en) 2011-03-18 2016-08-24 Alkermes Pharma Ireland Limited Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
US8742096B2 (en) 2011-03-28 2014-06-03 Demerx, Inc. Methods and compositions for preparing noribogaine from voacangine
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
AU2012308274B2 (en) 2011-09-15 2017-08-17 Demerx, Inc. Noribogaine salt ansolvates
CA2856551C (en) 2011-12-08 2021-06-22 Robert M. Moriarty Stereoselective total synthesis of noribogaine
WO2013085849A2 (en) 2011-12-09 2013-06-13 Demerx, Inc. Sulfate esters of noribogaine
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
JP2015506371A (ja) 2012-01-25 2015-03-02 デメルクス，インコーポレイテッド （１ｒ，４ｒ）７−オキソ−２−アザビシクロ［２．２．２］オクタ−５−エンおよびその誘導体
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
EP2693223B8 (en) 2012-08-03 2021-09-08 ABB Schweiz AG Voltage measurement device with an insulating body
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
CA2942638A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
WO2015126836A2 (en) 2014-02-18 2015-08-27 Demerx, Inc. Therapeutic methods employing noribogaine and related compounds
AU2014383143A1 (en) 2014-02-18 2016-09-29 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US20150246055A1 (en) 2014-03-03 2015-09-03 Demerx, Inc. Methods for acute and long-term treatment of opioid and opioid-like drug addiction
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US20150258105A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of alcohol dependence
US20150258108A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for reducing tolerance to opioid analgesics
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US20150258111A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for reducing tolerance to opioid analgesics using ibogaine and derivatives thereof
US20150258106A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse
US20150258114A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods for acute and long-term treatment of substance abuse using ibogaine
US20150258107A1 (en) 2014-03-13 2015-09-17 Demerx, Inc. Methods and compositions for treating depression
WO2015163844A1 (en) 2014-04-21 2015-10-29 Demerx, Inc. N-substituted noribogaine prodrugs
US20150342959A1 (en) 2014-06-03 2015-12-03 Demerx, Inc. Methods and compositions for sustained noribogaine treatment
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
AU2015353414B2 (en) 2014-11-26 2021-04-29 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
WO2016134019A1 (en) 2015-02-19 2016-08-25 Demerx, Inc. Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors

Also Published As

Publication number Publication date
US9744174B2 (en) 2017-08-29
WO2014144508A2 (en) 2014-09-18
WO2014143201A1 (en) 2014-09-18
EA201591679A1 (ru) 2016-05-31
US20140288056A1 (en) 2014-09-25
AU2014228986A1 (en) 2015-10-29
CN105307658A (zh) 2016-02-03
US20150045350A1 (en) 2015-02-12
US20160271139A1 (en) 2016-09-22
TW201505634A (zh) 2015-02-16
CA2942638A1 (en) 2014-09-18
EP2968355A2 (en) 2016-01-20
KR20150130461A (ko) 2015-11-23
AR095338A1 (es) 2015-10-07
ZA201507514B (en) 2018-05-30
JP2016514679A (ja) 2016-05-23
HK1220381A1 (zh) 2017-05-05
EP2968355A4 (en) 2016-08-24
CA2942511A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015022465A2 (pt) método para tratamento não-tóxico para síndrome de abstinência de drogas
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BR112016002646A2 (pt) dispositivos e métodos de entrega de fármaco de múltiplas unidades
IN2015DN03219A (pt)
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
BR112015017451A2 (pt) formulações farmacêuticas resistentes à violação
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
BR112016006188A2 (pt) método de tratamento com um protocolo de fármaco e um sistema com uma base de dados relacional acoplado a um ou mais dispositivos eletrônicos ; sistema para a gestão de um tratamento medicamentoso pela administração de um fármaco a um paciente e método de gestão de um tratamento com drogas usando um sistema de informação com uma base de dados relacional.
CL2015003343A1 (es) Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112015027477A2 (pt) método para tratamento de um transtorno de deglutição
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]